| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5190930
Max Phase: Preclinical
Molecular Formula: C30H24ClF3N6O2
Molecular Weight: 593.01
Associated Items:
Representations
Canonical SMILES: O=C(NCCNc1cc(-c2cn(-c3ccccc3)nc2-c2cccc(O)c2)ccn1)Nc1ccc(Cl)c(C(F)(F)F)c1
Standard InChI: InChI=1S/C30H24ClF3N6O2/c31-26-10-9-21(17-25(26)30(32,33)34)38-29(42)37-14-13-36-27-16-19(11-12-35-27)24-18-40(22-6-2-1-3-7-22)39-28(24)20-5-4-8-23(41)15-20/h1-12,15-18,41H,13-14H2,(H,35,36)(H2,37,38,42)
Standard InChI Key: HLWFBXQPNMBWJJ-UHFFFAOYSA-N
Associated Targets(Human)
c-Jun N-terminal kinase 3 3396 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 593.01 | Molecular Weight (Monoisotopic): 592.1601 | AlogP: 7.21 | #Rotatable Bonds: 8 |
| Polar Surface Area: 104.10 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 4 |
| #RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 9.55 | CX Basic pKa: 5.75 | CX LogP: 6.70 | CX LogD: 6.68 |
| Aromatic Rings: 5 | Heavy Atoms: 42 | QED Weighted: 0.14 | Np Likeness Score: -1.57 |
References
| 1. Abu Rabah RR, Sebastian A, Vunnam S, Sultan S, Tarazi H, Anbar HS, Shehata MK, Zaraei SO, Elgendy SM, Al Shamma SA, Omar HA, Al-Tel TH, El-Gamal MI.. (2022) Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors., 69 [PMID:35764033] [10.1016/j.bmc.2022.116894] |
Source
Source(1):